## Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

ENANTA PHARMACEUTICALS INC Form 4 December 06, 2013 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Or Yat Sun Issuer Symbol ENANTA PHARMACEUTICALS (Check all applicable) INC [ENTA] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X\_Officer (give title Other (specify (Month/Day/Year) below) below) C/O ENANTA 12/05/2013 Chief Scientific Officer PHARMACEUTICALS, INC., 500 ARSENAL STREET (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting WATERTOWN, MA 02472 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of TransactionAcquired (A) or Form: Direct Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code Disposed of (D) Beneficially (D) or Indirect Beneficial anv (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned (I) Ownership Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number orDerivative Securities Acquired ( or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	6. Date Exerce Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and 4	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 27.58	12/05/2013		А	35,000		<u>(1)</u>	12/05/2023	Common Stock	35,000
Reporting Owners										
F	Reporting Ow	ner Name / Address			Relat	ionsh	ips			
ŀ	Reporting Ow	ner Name / Address	Director	10% Ow			tips	Other		
Or Yat Su C/O ENA 500 ARSI	ın	RMACEUTICAL EET	Director	· 10% Ow	vner Offic	cer	iips Scientific Of			
Or Yat Su C/O ENA 500 ARSI	IN INTA PHAI ENAL STRI FOWN, MA	RMACEUTICAL EET	Director	· 10% Ow	vner Offic	cer	-			
Or Yat Su C/O ENA 500 ARSI WATERT <b>Signa</b>	n NTA PHAI ENAL STRI ΓΟWΝ, MA <b>tures</b> niel S. Gard	RMACEUTICAL EET . 02472	Director		vner Offic	cer	-			

## Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Such option will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become (1) exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from

the date of grant (December 5, 2013).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.